Krzystanek Marek, Martyniak Ewa, Pałasz Artur, Skałacka Katarzyna, Chwalba Artur, Wierzbiński Piotr
Department and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.
Department of Histology, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-752 Katowice, Poland.
Pharmaceuticals (Basel). 2023 Jun 19;16(6):897. doi: 10.3390/ph16060897.
Dysthymia is a common chronic mood disorder in which isolated symptoms of depression persist for at least 2 years. Despite the many medications recommended for the treatment of dysthymia, no recommendations have yet been made for the treatment of patients who fail to achieve clinical improvement. This justifies attempts to identify second-line drugs for the treatment of dysthymia. In an open and naturalistic case study, five patients diagnosed with dysthymia in whom at least one antidepressant treatment was ineffective were treated with amantadine. In the age- and gender-matched external control group, patients were treated with sertraline at 100 mg/day. Depressive symptoms were assessed using HDRS-17. Two men and three women were treated with 100 mg amantadine for 3 months with 3-5 months follow-up. After 1 month of treatment with amantadine, a significant reduction in the intensity of depressive symptoms was achieved in all patients, and the clinical improvement increased over the next 2 months of treatment. No deterioration in well-being was observed in any patient after discontinuation of amantadine. The effect of amantadine treatment was comparable to that of sertraline treatment in patients with dysthymia who improved with this drug. The present study indicates that amantadine is an effective and well-tolerated drug in the treatment of dysthymia. Amantadine may be associated with a quick improvement in symptoms in the treatment of dysthymia. Treatment with this drug seems to be associated with good tolerability and persistency of the therapeutic effect after the discontinuation of the treatment.
恶劣心境是一种常见的慢性情绪障碍，其中抑郁的孤立症状持续至少2年。尽管有许多药物被推荐用于治疗恶劣心境，但对于未能实现临床改善的患者的治疗尚未有相关推荐。这使得有理由尝试确定治疗恶劣心境的二线药物。在一项开放的自然主义病例研究中，对5名被诊断为恶劣心境且至少一种抗抑郁治疗无效的患者使用金刚烷胺进行治疗。在年龄和性别匹配的外部对照组中，患者接受100毫克/天的舍曲林治疗。使用汉密尔顿抑郁量表-17（HDRS-17）评估抑郁症状。两名男性和三名女性接受100毫克金刚烷胺治疗3个月，并随访3至5个月。在使用金刚烷胺治疗1个月后，所有患者的抑郁症状强度均显著降低，并且在接下来的2个月治疗中临床改善情况有所增加。停用金刚烷胺后，未观察到任何患者的幸福感恶化。在使用舍曲林治疗有效的恶劣心境患者中，金刚烷胺治疗的效果与之相当。本研究表明，金刚烷胺在治疗恶劣心境方面是一种有效且耐受性良好的药物。金刚烷胺在治疗恶劣心境时可能与症状的快速改善相关。使用这种药物治疗似乎与良好的耐受性以及停药后治疗效果的持续性相关。
